← All trials
NCT04297995
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2020
- Primary completion
- May 30, 2022
- Completion date
- Oct 31, 2023
- First posted
- Mar 6, 2020
- Last posted
- Mar 6, 2020
- Enrollment
- 56
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai Henlius BiotechLead sponsor
- Peking UniversityOverall official - principal investigator
- Harbin Medical UniversityOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Jiangsu Cancer Institute & HospitalOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.